Later, in 2020, the IRAP (International Registry of Anakinra for Pericarditis) study, a multicenter observational work, confirmed the efficacy and safety of Anakinra in the treatment of 224 colchicine-resistant and steroid-dependent patients affected by RP with high CRP values [40]. The gene discussed is CRP; the disease is pericarditis.